These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

350 related items for PubMed ID: 22157930

  • 1. Loss of ARID1A protein expression occurs as an early event in ovarian clear-cell carcinoma development and frequently coexists with PIK3CA mutations.
    Yamamoto S, Tsuda H, Takano M, Tamai S, Matsubara O.
    Mod Pathol; 2012 Apr; 25(4):615-24. PubMed ID: 22157930
    [Abstract] [Full Text] [Related]

  • 2. Accumulative copy number increase of MET drives tumor development and histological progression in a subset of ovarian clear-cell adenocarcinomas.
    Yamamoto S, Tsuda H, Miyai K, Takano M, Tamai S, Matsubara O.
    Mod Pathol; 2012 Jan; 25(1):122-30. PubMed ID: 21983935
    [Abstract] [Full Text] [Related]

  • 3. PIK3CA mutations and loss of ARID1A protein expression are early events in the development of cystic ovarian clear cell adenocarcinoma.
    Yamamoto S, Tsuda H, Takano M, Tamai S, Matsubara O.
    Virchows Arch; 2012 Jan; 460(1):77-87. PubMed ID: 22120431
    [Abstract] [Full Text] [Related]

  • 4.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 5. Mutation and loss of expression of ARID1A in uterine low-grade endometrioid carcinoma.
    Guan B, Mao TL, Panuganti PK, Kuhn E, Kurman RJ, Maeda D, Chen E, Jeng YM, Wang TL, Shih IeM.
    Am J Surg Pathol; 2011 May; 35(5):625-32. PubMed ID: 21412130
    [Abstract] [Full Text] [Related]

  • 6.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 7. PIK3CA mutation is an early event in the development of endometriosis-associated ovarian clear cell adenocarcinoma.
    Yamamoto S, Tsuda H, Takano M, Iwaya K, Tamai S, Matsubara O.
    J Pathol; 2011 Oct; 225(2):189-94. PubMed ID: 21735444
    [Abstract] [Full Text] [Related]

  • 8. Frequent somatic mutations of the telomerase reverse transcriptase promoter in ovarian clear cell carcinoma but not in other major types of gynaecological malignancy.
    Wu RC, Ayhan A, Maeda D, Kim KR, Clarke BA, Shaw P, Chui MH, Rosen B, Shih IeM, Wang TL.
    J Pathol; 2014 Mar; 232(4):473-81. PubMed ID: 24338723
    [Abstract] [Full Text] [Related]

  • 9. A functional proteogenomic analysis of endometrioid and clear cell carcinomas using reverse phase protein array and mutation analysis: protein expression is histotype-specific and loss of ARID1A/BAF250a is associated with AKT phosphorylation.
    Wiegand KC, Hennessy BT, Leung S, Wang Y, Ju Z, McGahren M, Kalloger SE, Finlayson S, Stemke-Hale K, Lu Y, Zhang F, Anglesio MS, Gilks B, Mills GB, Huntsman DG, Carey MS.
    BMC Cancer; 2014 Feb 22; 14():120. PubMed ID: 24559118
    [Abstract] [Full Text] [Related]

  • 10.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 11.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 12.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 13. Molecular alterations in endometrial and ovarian clear cell carcinomas: clinical impacts of telomerase reverse transcriptase promoter mutation.
    Huang HN, Chiang YC, Cheng WF, Chen CA, Lin MC, Kuo KT.
    Mod Pathol; 2015 Feb 22; 28(2):303-11. PubMed ID: 25081752
    [Abstract] [Full Text] [Related]

  • 14. Loss of ARID1A expression and its relationship with PI3K-Akt pathway alterations and ZNF217 amplification in ovarian clear cell carcinoma.
    Huang HN, Lin MC, Huang WC, Chiang YC, Kuo KT.
    Mod Pathol; 2014 Jul 22; 27(7):983-90. PubMed ID: 24336158
    [Abstract] [Full Text] [Related]

  • 15. Multifocal endometriotic lesions associated with cancer are clonal and carry a high mutation burden.
    Anglesio MS, Bashashati A, Wang YK, Senz J, Ha G, Yang W, Aniba MR, Prentice LM, Farahani H, Li Chang H, Karnezis AN, Marra MA, Yong PJ, Hirst M, Gilks B, Shah SP, Huntsman DG.
    J Pathol; 2015 Jun 22; 236(2):201-9. PubMed ID: 25692284
    [Abstract] [Full Text] [Related]

  • 16. Targeted sequencing of a specific gene panel detects a high frequency of ARID1A and PIK3CA mutations in ovarian clear cell carcinoma.
    Su YF, Tsai EM, Chen CC, Wu CC, Er TK.
    Clin Chim Acta; 2019 Jul 22; 494():1-7. PubMed ID: 30851247
    [Abstract] [Full Text] [Related]

  • 17.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 18.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 19. ARID1A mutations and PI3K/AKT pathway alterations in endometriosis and endometriosis-associated ovarian carcinomas.
    Samartzis EP, Noske A, Dedes KJ, Fink D, Imesch P.
    Int J Mol Sci; 2013 Sep 12; 14(9):18824-49. PubMed ID: 24036443
    [Abstract] [Full Text] [Related]

  • 20. ARID1A expression in ovarian clear cell carcinoma with an adenofibromatous component.
    Nishikimi K, Kiyokawa T, Tate S, Iwamoto M, Shozu M.
    Histopathology; 2015 Dec 12; 67(6):866-71. PubMed ID: 25913291
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 18.